Ramon Torres, M.D.

Latest by Ramon Torres, M.D.

CMV Retinitis Despite High CD4 Lymphocyte Counts

The question of how effective the repopulation of CD4 lymphocytes is in the prevention of reactivation of opportunistic infections in patients with advanced AIDS who have been placed on highly active antiretroviral therapy (HAART) was addressed by a ...

By Ramon Torres, M.D.

Lobucavir

A new anti-CMV agent manufactered by Bristol Myers Squibb, Inc. was presented at the 4th National Conference on Retroviruses and Opportunistic Infections. Lobucavir is a cyclobutyl analog of guanine with broad spectrum antiviral activity against most...

By Ramon Torres, M.D.

Pneumocystis Carinii Pneumonia: What's New in the Era of Combination Antiretroviral Therapies and Protease Inhibitors?

Despite the fact that the incidence and prevalence of Pneumocystis carinii pneumonia (PCP) among AIDS patients has declined over the years, due to the widespread use of prophylaxis, it remains an important cause of morbidity and mortality in advanced...

By Ramon Torres, M.D.